CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea News provided by Share this article Share this article SAN CARLOS, Calif., May 11, 2021 /PRNewswire/ -- CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea. The 12-week randomized double-blind vehicle-controlled trial is testing CAGE Bio's novel ionic-liquid based product CGB-400 Topical Gel. Patients diagnosed with moderate to severe rosacea...
Source: prnewswire.com